Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Short term Debt (2022)

Historic Short term Debt for RedHill Biopharma (RDHL) over the last 1 years, with Q4 2022 value amounting to $115.2 million.

  • RedHill Biopharma's Short term Debt changed N/A to $115.2 million in Q4 2022 from the same period last year, while for Dec 2022 it was $115.2 million, marking a year-over-year change of. This contributed to the annual value of $115.2 million for FY2022, which is N/A changed from last year.
  • According to the latest figures from Q4 2022, RedHill Biopharma's Short term Debt is $115.2 million.
  • RedHill Biopharma's 5-year Short term Debt high stood at $115.2 million for Q4 2022, and its period low was $115.2 million during Q4 2022.